{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T14:15:03Z","timestamp":1787235303938,"version":"build-2736575974"},"reference-count":40,"publisher":"The Endocrine Society","issue":"6","license":[{"start":{"date-parts":[[2024,8,28]],"date-time":"2024-08-28T00:00:00Z","timestamp":1724803200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,5,19]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Context<\/jats:title>\n                    <jats:p>The clinical manifestations of Cushing syndrome are variable, but an important number of patients present a metabolic syndrome, strongly associated with hepatic steatosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>The aim of this study was to determine the prevalence of metabolic dysfunction associated steatotic liver disease (MASLD) at the diagnosis of Cushing syndrome.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a single-center retrospective study at Angers Hospital (France) between 2010 and 2020. Forty-nine patients followed for Cushing syndrome with available abdominal imaging at diagnosis were included. A mean liver\/spleen density ratio &amp;lt;\u202f1 on computed tomography was diagnostic of hepatic steatosis. Simple clinico-biological scores predictive of hepatic fibrosis (FIB-4, NAFLD Fibrosis Score, and eLIFT) were calculated for patients with hepatic steatosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of the 49 patients, 13 (26.5%) had hepatic steatosis at diagnosis of Cushing syndrome. All 13 had MASLD. These patients had a higher prevalence of type 2 diabetes and higher triglyceride levels in multivariate analysis. There was no difference according to the intensity or duration of Cushing syndrome. Among the 13 patients with MASLD, 2 (15.4%) had a significant fibrosis predictive score. Of the 4 patients with follow-up imaging after remission of Cushing syndrome, 3 had remission of steatosis between 1 and 5 years after remission of Cushing syndrome. No patient without MASLD at diagnosis had a worsening liver\/spleen ratio after remission.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>We estimated the prevalence of hepatic steatosis at the diagnosis of Cushing syndrome at 26.5%. The presence of metabolic factors was associated with the occurrence of hepatic steatosis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1210\/clinem\/dgae568","type":"journal-article","created":{"date-parts":[[2024,8,27]],"date-time":"2024-08-27T10:37:26Z","timestamp":1724755046000},"page":"e2037-e2044","source":"Crossref","is-referenced-by-count":13,"title":["Fatty Liver Disease Along Cushing Syndrome Evolution"],"prefix":"10.1210","volume":"110","author":[{"given":"Maria","family":"Marengo","sequence":"first","affiliation":[{"name":"Department of Endocrinology, Diabetology and Nutrition, Angers University Hospital , 49100 Angers ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Briet","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Diabetology and Nutrition, Angers University Hospital , 49100 Angers ,","place":["France"]},{"name":"Angers University, MITOVASC, CarMe team, CNRS UMR 6015, INSERM U1083 , 49100 Angers ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathilde","family":"Munier","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Diabetology and Nutrition, Angers University Hospital , 49100 Angers ,","place":["France"]},{"name":"Angers University, MITOVASC, CarMe team, CNRS UMR 6015, INSERM U1083 , 49100 Angers ,","place":["France"]},{"name":"Centre de R\u00e9f\u00e9rence des Maladies Rares de la Thyro\u00efde et des R\u00e9cepteurs Hormonaux, University Hospital Angers , 49100 Angers ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00f4me","family":"Boursier","sequence":"additional","affiliation":[{"name":"Department of Hepato-Gastroenterology, Angers University Hospital , 49100 Angers ,","place":["France"]},{"name":"HIFIH Laboratory, Angers University, UPRES EA3859, SFR 4208 , 49100 Angers ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7785-5627","authenticated-orcid":false,"given":"Patrice","family":"Rodien","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Diabetology and Nutrition, Angers University Hospital , 49100 Angers ,","place":["France"]},{"name":"Angers University, MITOVASC, CarMe team, CNRS UMR 6015, INSERM U1083 , 49100 Angers ,","place":["France"]},{"name":"Centre de R\u00e9f\u00e9rence des Maladies Rares de la Thyro\u00efde et des R\u00e9cepteurs Hormonaux, University Hospital Angers , 49100 Angers ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1316-8190","authenticated-orcid":false,"given":"Valentine","family":"Suteau","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Diabetology and Nutrition, Angers University Hospital , 49100 Angers ,","place":["France"]},{"name":"Angers University, MITOVASC, CarMe team, CNRS UMR 6015, INSERM U1083 , 49100 Angers ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2024,8,28]]},"reference":[{"issue":"6","key":"2025052712551555400_dgae568-B1","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1016\/j.jhep.2023.06.003","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"79","author":"Rinella","year":"2023","journal-title":"J Hepatol"},{"issue":"4","key":"2025052712551555400_dgae568-B2","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","article-title":"The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review","volume":"77","author":"Younossi","year":"2023","journal-title":"Hepatology"},{"issue":"3","key":"2025052712551555400_dgae568-B3","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.jhep.2022.11.010","article-title":"A prospective study on the prevalence of NAFLD, advanced fibrosis, cirrhosis and hepatocellular carcinoma in people with type 2 diabetes","volume":"78","author":"Ajmera","year":"2023","journal-title":"J Hepatol"},{"issue":"3","key":"2025052712551555400_dgae568-B4","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.jhep.2018.10.033","article-title":"Non-alcoholic fatty liver disease\u2014a global public health perspective","volume":"70","author":"Younossi","year":"2019","journal-title":"J Hepatol"},{"issue":"4","key":"2025052712551555400_dgae568-B5","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/S2213-8587(18)30154-2","article-title":"Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies","volume":"7","author":"Stefan","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6","key":"2025052712551555400_dgae568-B6","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1053\/j.gastro.2020.01.043","article-title":"Association between fibrosis stage and outcomes of patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis","volume":"158","author":"Taylor","year":"2020","journal-title":"Gastroenterology"},{"issue":"6","key":"2025052712551555400_dgae568-B7","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/hep.20701","article-title":"Design and validation of a histological scoring system for nonalcoholic fatty liver disease","volume":"41","author":"Kleiner","year":"2005","journal-title":"Hepatology"},{"issue":"4","key":"2025052712551555400_dgae568-B8","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.jhep.2017.05.016","article-title":"Treatment of NAFLD with diet, physical activity and exercise","volume":"67","author":"Romero-G\u00f3mez","year":"2017","journal-title":"J Hepatol"},{"key":"2025052712551555400_dgae568-B9","doi-asserted-by":"crossref","first-page":"1087260","DOI":"10.3389\/fendo.2022.1087260","article-title":"Advancements in the treatment of non-alcoholic fatty liver disease (NAFLD)","volume":"13","author":"Rong","year":"2023","journal-title":"Front Endocrinol"},{"issue":"6","key":"2025052712551555400_dgae568-B10","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2309000","article-title":"A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis","volume":"390","author":"Harrison","year":"2024","journal-title":"N Engl J Med"},{"issue":"9996","key":"2025052712551555400_dgae568-B11","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/S0140-6736(14)61375-1","article-title":"Cushing's syndrome","volume":"386","author":"Lacroix","year":"2015","journal-title":"Lancet"},{"issue":"8","key":"2025052712551555400_dgae568-B12","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1210\/jc.2015-1818","article-title":"Treatment of Cushing's syndrome: an endocrine society clinical practice guideline","volume":"100","author":"Nieman","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"2025052712551555400_dgae568-B13","first-page":"4943","article-title":"Hepatic glucocorticoid receptor plays a greater role than adipose GR in metabolic syndrome despite renal compensation","volume":"157","author":"Bose","year":"2016","journal-title":"Nat Rev Endocrinol"},{"issue":"3","key":"2025052712551555400_dgae568-B14","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.cmet.2008.08.001","article-title":"The glucocorticoid receptor controls hepatic dyslipidemia through Hes1","volume":"8","author":"Lemke","year":"2008","journal-title":"Cell Metab"},{"issue":"1\u20132","key":"2025052712551555400_dgae568-B15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.mce.2012.03.026","article-title":"Hepatic growth hormone and glucocorticoid receptor signaling in body growth, steatosis and metabolic liver cancer development","volume":"361","author":"Mueller","year":"2012","journal-title":"Mol Cell Endocrinol"},{"issue":"1","key":"2025052712551555400_dgae568-B16","doi-asserted-by":"crossref","first-page":"C198","DOI":"10.1152\/ajpcell.00045.2010","article-title":"Adipogenic and lipolytic effects of chronic glucocorticoid exposure","volume":"300","author":"Campbell","year":"2011","journal-title":"Am J Physiol Cell Physiol"},{"key":"2025052712551555400_dgae568-B17","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1159\/000486002","article-title":"Metabolic syndrome in Cushing's syndrome patients","volume":"49","author":"Ferra\u00f9","year":"2018","journal-title":"Front Horm Res"},{"issue":"5","key":"2025052712551555400_dgae568-B18","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1194\/jlr.M013748","article-title":"Effects of antisense-mediated inhibition of 11\u03b2-hydroxysteroid dehydrogenase type 1 on hepatic lipid metabolism","volume":"52","author":"Li","year":"2011","journal-title":"J Lipid Res"},{"key":"2025052712551555400_dgae568-B19","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.jsbmb.2015.07.020","article-title":"Glucocorticoids and non-alcoholic fatty liver disease","volume":"154","author":"Woods","year":"2015","journal-title":"J Steroid Biochem Mol Biol"},{"key":"2025052712551555400_dgae568-B20","doi-asserted-by":"crossref","first-page":"7159696","DOI":"10.1155\/2019\/7159696","article-title":"Demographic characteristics, etiology, and comorbidities of patients with Cushing's syndrome: a 10-year retrospective study at a large general hospital in China","volume":"2019","author":"Zhou","year":"2019","journal-title":"Int J Endocrinol"},{"issue":"6","key":"2025052712551555400_dgae568-B21","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1530\/eje.0.1490543","article-title":"Hepatic steatosis in Cushing's syndrome: a radiological assessment using computed tomography","volume":"149","author":"Rockall","year":"2003","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"2025052712551555400_dgae568-B22","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s12020-018-1819-6","article-title":"Factors predicting long-term comorbidities in patients with Cushing's syndrome in remission","volume":"64","author":"Schernthaner-Reiter","year":"2019","journal-title":"Endocrine"},{"issue":"2","key":"2025052712551555400_dgae568-B23","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.ecl.2018.01.001","article-title":"Morbidity of Cushing's syndrome and impact of treatment","volume":"47","author":"Webb","year":"2018","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"5","key":"2025052712551555400_dgae568-B24","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1210\/jc.2008-0125","article-title":"The diagnosis of Cushing's syndrome: an endocrine society clinical practice guideline","volume":"93","author":"Nieman","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"2025052712551555400_dgae568-B25","author":"Andler"},{"issue":"1","key":"2025052712551555400_dgae568-B26","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/0149-936X(81)90054-0","article-title":"Computed tomography attenuation values in fatty liver","volume":"5","author":"Bydder","year":"1981","journal-title":"J Comput Tomogr"},{"issue":"3","key":"2025052712551555400_dgae568-B27","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1148\/radiology.137.3.6934563","article-title":"Difference between liver and spleen CT numbers in the normal adult: its usefulness in predicting the presence of diffuse liver disease","volume":"137","author":"Piekarski","year":"1980","journal-title":"Radiology"},{"issue":"5","key":"2025052712551555400_dgae568-B28","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","article-title":"AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease","volume":"77","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"issue":"4","key":"2025052712551555400_dgae568-B29","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1002\/hep.21496","article-title":"The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD","volume":"45","author":"Angulo","year":"2007","journal-title":"Hepatology"},{"issue":"6","key":"2025052712551555400_dgae568-B30","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1016\/j.jhep.2017.01.003","article-title":"A stepwise algorithm using an at-a-glance first-line test for the non-invasive diagnosis of advanced liver fibrosis and cirrhosis","volume":"66","author":"Boursier","year":"2017","journal-title":"J Hepatol"},{"issue":"2","key":"2025052712551555400_dgae568-B31","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1148\/radiol.2021204288","article-title":"Quantification of liver fat content with CT and MRI: state of the art","volume":"301","author":"Starekova","year":"2021","journal-title":"Radiology"},{"issue":"2","key":"2025052712551555400_dgae568-B32","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1053\/j.gastro.2020.04.048","article-title":"Prevalence and risk factors of nonalcoholic fatty liver disease and advanced fibrosis in general population: the French Nationwide NASH-CO Study","volume":"159","author":"Nabi","year":"2020","journal-title":"Gastroenterology"},{"issue":"8","key":"2025052712551555400_dgae568-B33","doi-asserted-by":"crossref","first-page":"G850","DOI":"10.1152\/ajpgi.00378.2011","article-title":"Consumption of a high-fat diet rapidly exacerbates the development of fatty liver disease that occurs with chronically elevated glucocorticoids","volume":"302","author":"D'souza","year":"2012","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"2025052712551555400_dgae568-B34","first-page":"6161348","article-title":"Effects of mifepristone on nonalcoholic fatty liver disease in a patient with a cortisol-secreting adrenal adenoma","volume":"2017","author":"Ragucci","year":"2017","journal-title":"Case Rep Endocrinol"},{"issue":"1","key":"2025052712551555400_dgae568-B35","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1530\/EJE-12-0252","article-title":"Nonalcoholic fatty liver disease in adult hypopituitary patients with GH deficiency and the impact of GH replacement therapy","volume":"167","author":"Nishizawa","year":"2012","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"2025052712551555400_dgae568-B36","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/nrendo.2018.10","article-title":"Direct effects of thyroid hormones on hepatic lipid metabolism","volume":"14","author":"Sinha","year":"2018","journal-title":"Nat Rev Endocrinol"},{"issue":"5","key":"2025052712551555400_dgae568-B37","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1002\/hep.29302","article-title":"Comparison of laboratory tests, ultrasound, or magnetic resonance elastography to detect fibrosis in patients with nonalcoholic fatty liver disease: a meta-analysis","volume":"66","author":"Xiao","year":"2017","journal-title":"Hepatology"},{"issue":"1","key":"2025052712551555400_dgae568-B38","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/S0168-8278(97)80288-7","article-title":"Noninvasive in vivo quantitative assessment of fat content in human liver","volume":"27","author":"Ricci","year":"1997","journal-title":"J Hepatol"},{"issue":"6","key":"2025052712551555400_dgae568-B39","doi-asserted-by":"crossref","first-page":"743","DOI":"10.3109\/00365528309182089","article-title":"Evaluation of liver steatotic and fibrous content by computerized tomography and ultrasound","volume":"18","author":"Pamilo","year":"1983","journal-title":"Scand J Gastroenterol"},{"issue":"1","key":"2025052712551555400_dgae568-B40","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1148\/radiol.2391050361","article-title":"Macrovesicular hepatic steatosis in living liver donors: use of CT for quantitative and qualitative assessment","volume":"239","author":"Park","year":"2006","journal-title":"Radiology"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgae568\/58996414\/dgae568.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/110\/6\/e2037\/58996414\/dgae568.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/110\/6\/e2037\/58996414\/dgae568.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T12:55:31Z","timestamp":1748350531000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/110\/6\/e2037\/7742936"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,28]]},"references-count":40,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,8,28]]},"published-print":{"date-parts":[[2025,5,19]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgae568","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,6]]},"published":{"date-parts":[[2024,8,28]]}}}